Table 10.

The impact of a quercetin-based nanoformulation on different pathogenic processes.

Nanoformulation	Pathogenesis	Types of Study	Cell Line/Animal	Outcome	Refs.
Quercetin liposomal nanoformulation	Ischemia and reperfusion injury	In vivo	Rat	This formulation prominently decreased inflammation markers and enhanced recovery.	[257]
Quercetin-loaded liposomes	Colorectal cancer	In vitro	SW48 colorectal cancer cells	This formulation decreased the viability of cancer better than the free compound. Furthermore, formulation-induced apoptosis was higher than free quercetin.	[258]
Quercetin-loaded nano-liposomes	Colon cancer	In vitro	HCT-116 p53+/+	Loaded liposomes exhibited higher antitumor action compared with free quercetin.	[259]
Quercetin liposomes	Diabetic retinopathy	In vivo	Rat	Quercetin liposomes allow for a decrease in disease symptoms of diabetic nephropathy.	[261]
Quercetin liposomes	Liver injury	In vivo	Mice	This formulation reduced liver function enzymes and oxidative stress,	[263]
Quercetin-containing liposomes-in-gel	Eczema	In vivo	Mice	Formulated liposomes caused a reduction in dermatopathology symptoms	[264]
Quercetin-incorporated micelles	Breast cancer	In vitro	MCF-7 cell line	Formulated micelles effectively in inhibited tumor cell growth.	[265]
Quercetin-loaded polymeric mixed micelles	Brain cancer	In vitro	C6 and U87MG	This formulation caused superior cellular uptake, induced apoptosis, and inhibited migration when tested against pure quercetin.	[266]
Gold-quercetin nanoparticles	Inflammation	In vitro	BV-2 cells	Nanoformulation decreased nitric oxide, proinflammatory prostaglandin, E2, and COX-2.	[269]
Quercetin-loaded cationic solid lipid nanoparticles	Bladder cancer	In vitro	T-24	Nanoformulation caused higher cytotoxicity.	[270]
Quercetin nanoemulsion	Alzheimer’s disease	In vivo	Rat	This compound protected neuronal dysfunction and improved histopathological changes.	[272]